Apogee Therapeutics Inc (APGE) PT Raised to $100 at Jefferies

Jefferies analyst Akash Tewari raised the price target on Apogee Therapeutics Inc (NASDAQ: APGE) to $100.00 (from $95.00) while maintaining a Buy rating.

The analyst comments "APGE reported APEX Ph2 Part A 52wk zumi maintenance data in AD - to us, the data looks strong: A) effect was maintained in week 16 responders w/ both Q3M & Q6M dosing, w/ EASI75 and IGA0/1 better than dupi and in-line w/ lebri at week 52; B) there are signs of deepening response in the overall pop (w/ Q3M numerically better) that approaches JAK-like efficacy, although need larger N & pbo-control; C) APGE is moving forward both Q3M & Q6M; D) Safety looks fine. Bottom line: APGE reported APEX Ph2 Part A 52wk zumi maintenance data in AD. There was some investor nervousness heading into the data around what the Q6M dose would look like, and conjunctivitis rates. Data came out this morning which we think looks solid."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'